2 Magnificent Dividend Stocks to Hold for the Next Decade
Novartis has increased its payout for 27 consecutive years thanks to a robust, innovation-driven business. Visa is an undisputed leader in its niche and still has strong growth prospects.
Novartis to buy radiology specialist Mariana Oncology for $1 billion
Novartis has entered an agreement to acquire US radiopharmaceutical company Mariana Oncology for $1 billion, the Swiss drug manufacturer said on Thursday.
Novartis to pay up to $1.75 billion for U.S. cancer-focused biotech
Pharmaceutical giant Novartis AG on Thursday said it will pay up to $1.75 billion for a U.S. biotech focused on cancer.
Why Novartis Stock Topped the Market on Tuesday
The pharmaceutical sector mainstay posted its first-quarter results. It beat on both the top and bottom lines.
Novartis raises full-year sales and profit guidance after strong Q1
Novartis AG (ADR) (NYSE:NVS) has raised its full-year revenue and profit guidance following a strong first quarter driven by momentum in key products including psoriasis drug Cosentyx, relapsing Mu...
Novartis CEO: Here's why we boosted our full-year guidance
Vas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss what feeds the company's strong guidance, if pricing in the U.S. will involve some friction, and more.
Novartis Exceeds Q1 Forecasts, Boosts Outlook as Blockbuster Drug Sales Climb
American depositary receipts (ADRs) of Novartis (NVS) rose in intraday trading Tuesday as the Swiss-based pharmaceutical firm reported better-than-expected first-quarter results and boosted its gui...
Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics
The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estim...
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Novartis (NVS) comfortably beats first-quarter earnings and sales estimates. The company ups its outlook for 2024 on strong growth across key brands.
Novartis CEO: Broadly Positive About Business Momentum
Novartis CEO Vas Narasimhan said the company saw a very good performance across both established medicines and recent drug launches. "While there was a small contribution from generics getting push...
Novartis shares jump as drugmaker boosts outlook
Novartis shares rallied on Tuesday as the Swiss drugmaker raised its outlook for the year after seeing strong demand for heart and psoriasis drugs.
Shares of Novartis climb 4.8% on raised guidance, better-than-expected results
Shares of Swiss drugmaker Novartis climbed 4.8% in early deals Tuesday after it raised its full-year guidance following better-than-expected first-quarter results.
Novartis Ups Guidance on Profit, Sales Growth
Novartis lifted its full-year guidance after first-quarter profit and sales rose and beat consensus expectations, boosted by strong sales of key drugs.
Novartis lifts FY guidance after Q1 results beat expectations
Swiss drugmaker Novartis on Tuesday raised its full-year guidance after reporting better-than-expected first-quarter results.
Novartis (NVS) to Report Q1 Earnings: What to Expect?
Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.
Related Companies